Cardiovascular diseases (CVDs) are the leading causes of morbidity and mortality in individuals with type 2 diabetes mellitus (T2DM). Secular changes in CVD outcomes have occurred over the past few ...
The management of type 2 diabetes mellitus (T2DM) is becoming increasingly complex. Sodium–glucose cotransporter type 2 inhibitors (SGLT2is) are the newest antidiabetic agents for T2DM. By targeting ...
This activity is jointly provided by Partners for Advancing Clinical Education and Cardiometabolic Health Congress. Supported by an independent medical educational grant from Abbott Diabetes Care, Inc ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results